The first project under the new collaboration involves the continued development of BHB’s new genetic-based risk assessment test for colorectal cancer with clinical validation support provided by CRL’s CLIA-certified laboratory services.
BHB will combine its bioinformatics and qPCR assay development team with CRL’s molecular lab testing experience to create new molecular diagnostic tests.
BHB CEO Robert Phelps said CRL’s CLIA-certified testing services accelerate their development plans by leveraging on their expertise and laboratory.
CRL Molecular Diagnostics executive director Heather Fehling said BHB’s visionary approach to bioinformatics and assay development presents an exciting opportunity for CRL.
BHB manufactures software and consumables for purposes of genetic research in areas of cancer, stem cell research, immunology, metabolism, and specific neurological disorders.
CRL is a privately held reference laboratory in Lenexa, Kansas offering testing services in the areas of clinical trials, corporate wellness programs, genomics, insurance, molecular diagnostics, bioanalytics and toxicology.
